Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, shared her thoughts on the current research regarding Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2) inhibitors in chronic lymphocytic leukemia (CLL) and what providers should keep in mind before prescribing them.
Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center and an institute physician at Dana-Farber Cancer Institute, gave insight into provider considerations for prescribing Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2) inhibitors to patients with chronic lymphocytic leukemia (CLL) at the annual meeting of the European Hematology Association in Frankfurt, Germany.
Transcript
In CLL, we are seeing the use of second-generation BTK inhibitors, use of BTK inhibition alongside BCL-2 inhibitors, and studies of third-generation BTK inhibitors. What are the key considerations for clinicians in selecting a therapeutic approach?
Right now, in the frontline setting in the United States, it's really primarily continuous BTK inhibition with a second-generation inhibitor, essentially acalabrutinib or zanubrutinib, vs time-limited therapy with venetoclax/obinutuzumab. We don't have approval yet for BTK or BCL-2 [inhibitors], and the data really showed pretty similar progression-free survival for BTK/BCL-2 as for venetoclax/obinutuzumab. So I think, at present, it's really quite reasonable to stick with venetoclax/obinutuzumab as a time-limited regimen.
For patients with p53 aberration, we do favor [a] continuous BTK inhibitor. And for patients with mutated favorable risk IGHV [immunogloblulin heavy chain], I certainly favor time-limited therapy because they have a good likelihood of achieving undetectable MRD [minimal residual disease] and then a very prolonged remission off therapy.
For all the patients in between, it's something of a long discussion—taking into account their particular risk factors, their goals, and desires. For example, often young patients are happy to come in a lot, do the extra work of a time-limited regimen where sometimes the older patients, they don't want to do that, they just want to go on a BTK inhibitor and more or less be done with their monitoring. And so all of these factors come into play. It's a lengthy discussion with the patient, really.
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Posters Detail Effects—and Uncertainty—of Drug Pricing Negotiations
May 7th 2024Research into the Inflation Reduction Act evaluated payer concerns, patient and physician behavior, which patients will benefit from the first 10 drugs selected for price negotiation, and the ripple effect into Medicaid at the state level.
Read More